Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Holding(s) in Company

6 Feb 2007 11:24

ReNeuron Group plc06 February 2007 TR-1(i): NOTIFICATION OF MAJOR INTERESTS IN SHARES (1). Identity of the issuer or the underlying issuer of existing shares to whichvoting rights are attached (ii): RENEURON GROUP PLC 2. Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights: ( X ) An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached: ( ) An event changing the breakdown of voting rights: ( ) Other (please specify) : ( ) ................. 3. Full name of person(s) subject to the notification obligation (iii): TOSCAFIELD LIMITED 4. Full name of shareholder(s) (if different from 3.) (iv): NOT SPECIFIED. 5. Date of the transaction and date on which the threshold is crossed or reachedif different) (v): NOT SPECIFIED. 6. Date on which issuer notified: 2 FEBRUARY 2007 7. Threshold(s) that is/are crossed or reached: ................. 8. Notified details: ................. A: Voting rights attached to shares Class/type of shares Situation previous to if possible using the the Triggering ISIN CODE transaction (vi) Number of shares Number of voting Rights (viii) ORDINARY 9,950,000 9,950,000 SHARES Resulting situation after the triggering transaction (vii) Class/type of shares Number of shares Number of voting rights % of voting rights if possible using (ix) the ISIN CODE Direct Direct (x) Indirect (xi) Direct Indirect 0 0 0 0% 0 B: Financial Instruments Resulting situation after the triggering transaction (xii) Type of Expiration Date Exercise/Conversion Number of voting % of voting financial (xiii) Period/ Date (xiv) rights that may be rights instrument acquired if the instrument is exercised/ converted. N/A - - - - Total (A+B)Number of voting % of voting rights rights 0 0% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable (xv): NONE SPECIFIED. Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A 12. Date on which proxy holder will cease to hold voting rights: N/A 13. Additional information: RECENT DISPOSAL. 14. Contact name: MICHAEL HUNT, CEO 15. Contact telephone number: 01483 302560 Annex Notification Of Major Interests In Shares (XVI) A: Identity of the person or legal entity subject to the notification obligation Full name (including legal form for legal entities): TOSCAFIELD LIMITED Contact address (registered office for legal entities): 7TH FLOOR, 90 LONGACRE, LONDON WC2E 9RA Phone number: 020 7845 6100 Other useful information (at least legal representative for legal persons): - B: Identity of the notifier, if applicable (xvii) Full name: N/A Contact address: N/A Phone number: N/A Other useful information (e.g. functional relationship with the person or legalentity subject to the notification obligation): N/A C: Additional information : N/A This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
2nd Sep 20247:00 amRNSCancellation - ReNeuron Group Plc
30th Aug 20247:00 amRNSCorporate update and AIM cancellation
2nd Aug 202412:25 pmRNSCorporate Update
26th Jun 20243:33 pmRNSChange of Registered Address
5th Jun 20243:36 pmRNSCreditor’s decision on Administrators' Proposals
17th May 202412:45 pmRNSPublication of Joint Administrators' Proposals
8th May 20247:00 amRNSUpdate on Administration Process
17th Apr 202411:30 amRNSDirectorate Change
20th Mar 20243:43 pmRNSAppointment of Administrators
20th Mar 202412:30 pmRNSIntention to Appoint Administrators
1st Mar 20247:00 amRNSBlock Listing Review & Total Voting Rights
5th Feb 20242:30 pmRNSCorporate update and suspension of trading on AIM
5th Feb 20242:30 pmRNSSuspension - ReNeuron Group plc
27th Nov 20238:53 amEQSEdison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™
8th Nov 20237:01 amRNSInterim Results for the six months ended 30 Sept
8th Nov 20237:00 amRNSReNeuron presents in vivo data at Cell 2023
4th Sep 20237:00 amRNSR&D Update
1st Sep 20237:00 amRNSBlock Listing Review & Total Voting Rights
29th Aug 20237:00 amRNSDirector declaration
22nd Aug 202310:34 amRNSResult of AGM
24th Jul 20235:20 pmRNSNotice of AGM
12th Jul 202311:57 amRNSShare Purchase by Chief Financial Officer
16th Jun 20235:12 pmRNSShare Purchase by Senior Independent NED
16th Jun 20232:26 pmRNSShare Purchase by Executive Chairman
16th Jun 20237:00 amRNSPosting of Annual Report & Accounts
5th Jun 20234:30 pmRNSHolding(s) in Company
25th May 20237:00 amRNSUnaudited Preliminary Results
18th May 20237:00 amRNSNotice of Results
17th May 20238:56 amRNSHolding(s) in Company
27th Apr 20238:18 amRNSHolding(s) in Company
6th Apr 20234:17 pmRNSShare Purchase by Senior Independent NED
3rd Apr 20237:00 amRNSNew Scientific Advisory Board
28th Mar 20232:23 pmRNSDirector/PDMR Shareholding
23rd Mar 20237:00 amRNSChange of adviser
13th Mar 20237:00 amRNSReNeuron to present at Advanced Therapies 2023
9th Mar 20234:03 pmRNSHolding(s) in Company
3rd Mar 20239:37 amRNSShare Purchase by Chief Financial Officer
1st Mar 20237:01 amRNSBlock listing application
1st Mar 20237:00 amRNSBlock Listing Review & Total Voting Rights
24th Feb 202311:20 amRNSDirector Share Purchases
15th Feb 20237:00 amRNSGrant of Options
30th Jan 20234:38 pmRNSDirector/PDMR Shareholding
27th Jan 202311:05 amRNSSecond Price Monitoring Extn
27th Jan 202311:00 amRNSPrice Monitoring Extension
24th Jan 202310:55 amRNSShare Purchase by Chief Financial Officer
23rd Jan 20233:04 pmRNSShare Purchase by Executive Chairman
19th Jan 20237:00 amRNSCompany restructuring update
3rd Jan 20237:02 amRNSTotal Voting Rights
3rd Jan 20237:00 amRNSDirectorate Change
12th Dec 20222:31 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.